Sold as Mefoxin, Mefoxin In Sodium Chloride 0.9% In Plastic Container, Mefoxin In Dextrose 5% In Plastic Container, Cefoxitin And Dextrose In Duplex Container. Every FDA application for this active ingredient: 3 branded and 15 generic.
As of Nov 15, 2026, FDA lists 18 applications for Cefoxitin Sodium (sold as Mefoxin, Mefoxin In Sodium Chloride 0.9% In Plastic Container, Mefoxin In Dextrose 5% In Plastic Container and others), first approved Oct 18, 1978, with 2 new uses approved and 0 published complete response letters.
| Cefoxitin | Part D | $408K | +5% | 337 |
| Cefoxitin | Part B | $14K | -20% | 359 |
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform TrialMycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection · The University of Queensland | Phase 2 | Not yet recruiting | Mar 20, 2026 |
| Duration of Perioperative Antibiotics in PancreatoduodenectomyPancreatoduodenectomy, PPPD · Asan Medical Center | Not applicable | Enrolling by invitation | Jun 29, 2025 |
| Finding the Optimal Regimen for Mycobacterium Abscessus TreatmentPulmonary Disease Due to Mycobacteria (Diagnosis) · The University of Queensland | Phase 2 / Phase 3 | Recruiting | Mar 17, 2020 |
| Oct 18, 1978 | MefoxinNDA 50517 · New molecular entity | Pharmobedient | 21 | Discontinued |
| Jan 8, 1987 | MefoxinANDA 62757 | Pharmobedient | 21 | Discontinued |
| Jan 25, 1993 | Mefoxin In Plastic ContainerANDA 63182 | Pharmobedient | 16 | Discontinued |
| Jul 3, 2000 | CefoxitinANDA 65011 | Fresenius Kabi USA | 4 | Discontinued |
| Jul 3, 2000 | CefoxitinANDA 65012 | Fresenius Kabi USA | 4 | Discontinued |
| Sep 11, 2000 | CefoxitinANDA 65050 | Hikma | 2 | Marketed |
| Sep 11, 2000 | CefoxitinANDA 65051 | Hikma | 1 | Marketed |
| Jan 23, 2006 | CefoxitinANDA 65313 | Hospira Inc | 2 | Discontinued |
| Feb 13, 2006 | CefoxitinANDA 65312 | Hospira Inc | 2 | Discontinued |
| Mar 10, 2006 | Cefoxitin And Dextrose In Duplex ContainerNDA 65214 | B Braun | 6 | Marketed |
| Jun 12, 2009 | CefoxitinANDA 65414 | Acs Dobfar | 1 | Marketed |
| Feb 26, 2010 | CefoxitinANDA 65239 | Hikma Farmaceutica | 0 | Marketed |
| Mar 12, 2010 | CefoxitinANDA 65238 | Hikma Farmaceutica | 3 | Marketed |
| May 19, 2010 | CefoxitinANDA 65415 | Acs Dobfar | 1 | Marketed |
| Aug 31, 2011 | CefoxitinANDA 65464 | Acs Dobfar Spa | 1 | Discontinued |
| Aug 31, 2011 | CefoxitinANDA 65467 | Acs Dobfar Spa | 1 | Discontinued |
| Nov 16, 2015 | Cefoxitin In Plastic ContainerANDA 200938 | Samson Medcl | 0 | Marketed |
| — | Mefoxin In Sodium Chloride 0.9% In Plastic Container, Mefoxin In Dextrose 5% In Plastic ContainerNDA 50581 | Merck | 1 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Fresenius Kabi USA
Hikma